Following the completion of chemotherapy, patients diagnosed with hormone receptor-positive breast cancer are recommended to undergo endocrine therapy, while HER2+ breast cancer patients should receive a combination of trastuzumab and chemotherapy [89]. Here, ERBB2 is linked to breast cancer.